Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy

Diabetic retinopathy affects 8 million Americans with diabetes and proliferative diabetic retinopathy (PDR) is associated with severe vision loss. The Diabetic Retinopathy Study (DRS) established panretinal photocoagulation (PRP) as an effective treatment for PDR. Reports including randomized clinical trials1,2 have established intravitreal ranibizumab (IVR) as a noninferior treatment option for PDR. The Diabetic Retinopathy Clinical Research (DRCR) Protocol S showed that eyes treated with IVR had less macular edema, visual field loss, and need for pars plana vitrectomy compared with PRP.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: Reports Source Type: research